Although current therapeutic strategies such as SGLT2i, GLP-1 RA, renin-angiotensin system blockade, tolvaptan (vasopressin receptor 2 antagonist), atrasentan (endothelin-1 blocker), or finerenone (non-steroidal anti-mineralocorticoid) can decelerate CKD, none are capable of halting disease progression [3, 41]. This evidence concerns the gene GLP1R and chronic kidney disease.